PL2716642T3 - Związki imidazopirydyny - Google Patents
Związki imidazopirydynyInfo
- Publication number
- PL2716642T3 PL2716642T3 PL12791965T PL12791965T PL2716642T3 PL 2716642 T3 PL2716642 T3 PL 2716642T3 PL 12791965 T PL12791965 T PL 12791965T PL 12791965 T PL12791965 T PL 12791965T PL 2716642 T3 PL2716642 T3 PL 2716642T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazopyridine compound
- imidazopyridine
- compound
- Prior art date
Links
- -1 Imidazopyridine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011119826 | 2011-05-30 | ||
| JP2011287682 | 2011-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2716642T3 true PL2716642T3 (pl) | 2017-01-31 |
Family
ID=47259254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12791965T PL2716642T3 (pl) | 2011-05-30 | 2012-05-29 | Związki imidazopirydyny |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9447090B2 (pl) |
| EP (1) | EP2716642B1 (pl) |
| JP (1) | JP5975025B2 (pl) |
| KR (1) | KR20140040774A (pl) |
| CN (1) | CN103608347B (pl) |
| AR (1) | AR086589A1 (pl) |
| BR (1) | BR112013030909A2 (pl) |
| CA (1) | CA2836202A1 (pl) |
| EA (1) | EA201391769A1 (pl) |
| ES (1) | ES2597034T3 (pl) |
| IL (1) | IL229513A0 (pl) |
| MX (1) | MX2013014082A (pl) |
| PH (1) | PH12013502419A1 (pl) |
| PL (1) | PL2716642T3 (pl) |
| PT (1) | PT2716642T (pl) |
| TW (1) | TW201311685A (pl) |
| WO (1) | WO2012165399A1 (pl) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| JP6118965B2 (ja) * | 2012-04-16 | 2017-04-26 | トーアエイヨー株式会社 | ２環性化合物 |
| MY173949A (en) | 2012-04-25 | 2020-02-28 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
| CN103508918B (zh) * | 2012-06-18 | 2015-09-09 | 上海医药工业研究院 | 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法 |
| US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) * | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US8796305B2 (en) * | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| CA2891976C (en) | 2012-11-30 | 2020-07-21 | Astellas Pharma Inc. | Imidazopyridine compounds |
| US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3004094B1 (de) * | 2013-06-04 | 2017-03-01 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| EA201600096A1 (ru) | 2013-07-10 | 2016-10-31 | Байер Фарма Акциенгезельшафт | Бензил-1н-пиразол[3,4-b]пиридины и их применение |
| US20160159808A1 (en) * | 2013-07-24 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| ES2644784T3 (es) * | 2013-08-08 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso |
| JP2016527295A (ja) * | 2013-08-08 | 2016-09-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換イミダゾ［１，２−ａ］ピラジンカルボキサミドおよびその使用 |
| WO2015082411A1 (de) * | 2013-12-05 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung |
| US20160324856A1 (en) | 2014-01-13 | 2016-11-10 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of neuromuscular disorders |
| EP3107920B1 (de) * | 2014-02-19 | 2017-10-18 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
| CA2943051A1 (en) * | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| CA2943005A1 (en) * | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| WO2015165930A1 (de) | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen |
| US20170050962A1 (en) * | 2014-05-02 | 2017-02-23 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]pyridines as stimulators of soluble guanylate cyclase for treating cardiovascular diseases |
| JP2017514900A (ja) * | 2014-05-02 | 2017-06-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | ６−置換イミダゾ［１，２−ａ］ピリジンカルボキサミドおよびその使用 |
| WO2015165970A1 (de) * | 2014-05-02 | 2015-11-05 | Bayer Pharma Aktiengesellschaft | 6-chlor-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| CN103965193B (zh) * | 2014-05-30 | 2016-04-06 | 浙江司太立制药股份有限公司 | N-(苯氧烷基)咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 |
| US10174021B2 (en) * | 2014-12-02 | 2019-01-08 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolo[1,5-A]pyridines and their use |
| CN107001361A (zh) * | 2014-12-02 | 2017-08-01 | 拜耳医药股份有限公司 | 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途 |
| WO2016101118A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
| EA201792346A1 (ru) | 2015-05-06 | 2018-05-31 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОТДЕЛЬНО И В КОМБИНАЦИЯХ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ ПАЛЬЦЕВИДНЫХ ЯЗВ (DU), СОПУТСТВУЮЩИХ СИСТЕМНОМУ СКЛЕРОЗУ (SSc) |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
| IL257743B (en) | 2015-09-17 | 2022-08-01 | Marvin J Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| MX2018007152A (es) | 2015-12-14 | 2018-08-15 | Ironwood Pharmaceuticals Inc | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. |
| CN110022871A (zh) | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品 |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| EP3554488A2 (en) | 2016-12-13 | 2019-10-23 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7314173B2 (ja) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 |
| BR112020022340A2 (pt) | 2018-05-15 | 2021-02-02 | Bayer Aktiengesellschaft | benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| US12220414B2 (en) | 2018-07-11 | 2025-02-11 | Tisento Therapeutics Inc. | Use of sGC stimulators for the treatment of mitochondrial disorders |
| CA3126778A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| CN111518061B (zh) * | 2019-02-01 | 2023-08-25 | 鲁南制药集团股份有限公司 | 一种(e)-3-(3-呋喃基)丙烯酸的制备方法 |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN119367368B (zh) * | 2024-11-28 | 2025-12-05 | 中山大学 | 氮杂四元环连接的吡唑并吡啶类化合物在制备治疗肺动脉高压的药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07242666A (ja) * | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
| SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| WO1999063929A2 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| AU1161601A (en) | 1999-11-05 | 2001-05-14 | University College London | Activators of soluble guanylate cyclase |
| DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
| CA2311483A1 (en) | 2000-06-12 | 2001-12-12 | Gregory N Beatch | IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF |
| DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
| WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
| DE102006020327A1 (de) | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102006054757A1 (de) | 2006-11-21 | 2008-05-29 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
| RU2576662C2 (ru) * | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
-
2012
- 2012-05-29 PL PL12791965T patent/PL2716642T3/pl unknown
- 2012-05-29 BR BR112013030909A patent/BR112013030909A2/pt not_active IP Right Cessation
- 2012-05-29 CA CA2836202A patent/CA2836202A1/en not_active Abandoned
- 2012-05-29 KR KR1020137034903A patent/KR20140040774A/ko not_active Withdrawn
- 2012-05-29 JP JP2013518087A patent/JP5975025B2/ja not_active Expired - Fee Related
- 2012-05-29 EA EA201391769A patent/EA201391769A1/ru unknown
- 2012-05-29 WO PCT/JP2012/063695 patent/WO2012165399A1/ja not_active Ceased
- 2012-05-29 EP EP12791965.2A patent/EP2716642B1/en active Active
- 2012-05-29 TW TW101119128A patent/TW201311685A/zh unknown
- 2012-05-29 PH PH1/2013/502419A patent/PH12013502419A1/en unknown
- 2012-05-29 ES ES12791965.2T patent/ES2597034T3/es active Active
- 2012-05-29 AR ARP120101881A patent/AR086589A1/es not_active Application Discontinuation
- 2012-05-29 MX MX2013014082A patent/MX2013014082A/es unknown
- 2012-05-29 CN CN201280026953.4A patent/CN103608347B/zh not_active Expired - Fee Related
- 2012-05-29 PT PT127919652T patent/PT2716642T/pt unknown
-
2013
- 2013-11-20 IL IL229513A patent/IL229513A0/en unknown
- 2013-11-26 US US14/090,074 patent/US9447090B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2716642A1 (en) | 2014-04-09 |
| US9447090B2 (en) | 2016-09-20 |
| CN103608347A (zh) | 2014-02-26 |
| IL229513A0 (en) | 2014-01-30 |
| EP2716642A4 (en) | 2014-12-03 |
| PH12013502419A1 (en) | 2014-01-06 |
| EP2716642B1 (en) | 2016-07-20 |
| MX2013014082A (es) | 2014-03-21 |
| PT2716642T (pt) | 2016-10-17 |
| WO2012165399A1 (ja) | 2012-12-06 |
| CN103608347B (zh) | 2016-04-27 |
| ES2597034T3 (es) | 2017-01-13 |
| TW201311685A (zh) | 2013-03-16 |
| AR086589A1 (es) | 2014-01-08 |
| BR112013030909A2 (pt) | 2016-12-06 |
| JPWO2012165399A1 (ja) | 2015-02-23 |
| US20140088080A1 (en) | 2014-03-27 |
| CA2836202A1 (en) | 2012-12-06 |
| JP5975025B2 (ja) | 2016-08-23 |
| EA201391769A1 (ru) | 2014-04-30 |
| KR20140040774A (ko) | 2014-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2716642T (pt) | Composto de imidazopiridina | |
| ZA201401553B (en) | Cyclopropaneamine compound | |
| IL233154A0 (en) | compounds | |
| GB201106395D0 (en) | Compounds | |
| GB201109763D0 (en) | Compounds | |
| GB201106817D0 (en) | New compound | |
| ZA201306857B (en) | Mesogen-containing compounds | |
| ZA201503794B (en) | Imidazopyridine compounds | |
| AP3491A (en) | Triazolopyridines | |
| GB201107197D0 (en) | Compounds | |
| GB201122139D0 (en) | Compounds | |
| EP2708540A4 (en) | PYRIMIDO-DIAZEPINONE COMPOUND | |
| GB201122305D0 (en) | Novel compound | |
| GB201110938D0 (en) | Compounds | |
| GB201105659D0 (en) | Compounds | |
| GB201104669D0 (en) | Compound | |
| GB201118613D0 (en) | Compounds | |
| GB201112987D0 (en) | Novel compound | |
| AU2012263575A1 (en) | Imidazopyridine compound | |
| GB201121538D0 (en) | Compound | |
| GB201118102D0 (en) | Compound | |
| GB201111440D0 (en) | Compounds | |
| GB201119703D0 (en) | Compounds | |
| GB201119745D0 (en) | Compounds | |
| GB201120805D0 (en) | Compounds |